<DOC>
	<DOC>NCT01152606</DOC>
	<brief_summary>This is a single cohort observational safety study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study. Data will be collected from centre's medical records for up to 5 years or death.</brief_summary>
	<brief_title>A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>All patients who are considered candidates to receive Herceptin for this indication Patients for whom Herceptin is contraindicated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>